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Parathyroid hormone (PTH) promotes bone catabo-
lism by targeting bone marrow (BM) stromal cells
(SCs) and their osteoblastic progeny. Here we show
that a continuous infusion of PTH that mimics hyper-
parathyroidism fails to induce osteoclast formation,
bone resorption, and cortical bone loss in mice lack-
ing T cells. T cells provide proliferative and survival
cues to SCs and sensitize SCs to PTH through
CD40 ligand (CD40L), a surfacemolecule of activated
T cells that induces CD40 signaling in SCs. As a re-
sult, deletion of T cells or T cell-expressed CD40L
blunts the bone catabolic activity of PTH by decreas-
ing bone marrow SC number, the receptor activator
of nuclear factor-kB ligand (RANKL)/OSTEOPROTE
GERN (OPG) ratio, and osteoclastogenic activity.
Therefore, T cells play an essential permissive role
in hyperparathyroidism as they influence SC prolifer-
ation, life span, and function through CD40L. T cell-
SC crosstalk pathways may thus provide pharmaco-
logical targets for PTH-induced bone disease.
INTRODUCTION
Chronic excessive production of parathyroid hormone (PTH) is
a cause of skeletal and extraskeletal disease. Secondary hyper-
parathyroidism has been implicated in the pathogenesis of senile
osteoporosis (Riggs and Melton, 1986), while primary hyper-
parathyroidism (PHP), is associated with accelerated bone loss
(Grey et al., 1996), osteopenia (Parisien et al., 2001; Potts,
1998; Silverberg et al., 1989), and increased bone turnover
(Parisien et al., 2001), an independent risk factor for fractures.
Furthermore, PHP is a cause of extraskeletal manifestations
stemming from increased bone resorption such as hypercalce-
mia, recurrent nephrolithiasis, renal failure, peptic ulcers, and
mental changes (Potts, 1998).
PHP and secondary hyperparathyroidism are mimicked by
continuous PTH infusion, while intermittent PTH administration
is an approved treatment modality for osteoporosis (Canalis
et al., 2007). Both continuous PTH and intermittent PTH increase
bone turnover in trabecular and cortical bone, as evidenced by
elevations in histomorphometric and biochemical markers of132 Cell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc.resorption and formation (Dempster et al., 1999; Iida-Klein
et al., 2005; Zhou et al., 2001). PHP and continuous PTH treat-
ment cause cortical bone loss by enhancing endosteal resorp-
tion through stimulation of osteoclast (OC) formation and activity
(Iida-Klein et al., 2005; Lotinun et al., 2004; Potts, 1998). Severe
chronic elevations of PTH levelsmay also lead to trabecular bone
loss (Iida-Klein et al., 2005; Potts, 1998), although PHP and con-
tinuous PTH treatment often induce amodest increase in cancel-
lous bone (Parisien et al., 2001; Silverberg et al., 1989; Zhou
et al., 2001). In contrast, intermittent PTH treatment markedly
increase trabecular bone volume due to a preponderant stimula-
tion of trabecular bone formation and causes a small loss of
cortical bone (Dempster et al., 1993; Neer et al., 2001).
The biological activities of PTH result from its binding to the
PTH/PTH-related protein (PTHrP) receptor (PPR or PTH-1R),
expressed on bone marrow (BM) SCs and their osteoblastic
progeny (Calvi et al., 2001; Qin et al., 2004). The catabolic effect
of PTH has been shown to be mediated, in part, by enhanced
production of RANKL and (macrophage colony stimulating fac-
tor) M-CSF, and decreased production of OPG by SCs and
osteoblasts (OBs) (Ma et al., 2001; Weir et al., 1996). However,
additional BM cells may contribute to the catabolic activity of
PTH in vivo. Among them are activated T cells (Clark and
Normansell, 1990; Di Rosa and Pabst, 2005), a lineage now
known to regulate bone homeostasis through secretion of pro-
and antiosteoclastogenic factors (Clowes et al., 2005; Teitel-
baum, 2004; Weitzmann and Pacifici, 2005). Activated T cells
also express surface ligands that bind to and activate counter-
receptors found on the surface of cells of the osteoblastic line-
age (Ahuja et al., 2003). One of these T cell ligands is CD40L,
which upon ligation to SC andOB expressedCD40 provides sur-
vival cues to these cells (Ahuja et al., 2003). Furthermore, T cells
promote the capacity of osteoblastic cells to support OC forma-
tion by increasing the differentiation of SCs into OBs (Rifas and
Arackal, 2003; Rifas et al., 2003), and by augmenting the SC/
OB production of osteoclastogenic cytokines (Rifas and Avioli,
1999). These data suggest a model whereby T lymphocytes
function as permissive cells that increase the capacity of SCs
and OBs to support PTH-induced osteoclastogenesis by pro-
moting their survival and cytokine production. We thus investi-
gated whether T cells facilitate PTH-induced cortical bone loss
by increasing the responsiveness of SCs to PTH. We show that
continuous PTH treatment at doses that elevate serum PTH to
levels typical of PHP stimulates OC formation and bone resorp-
tion and induces cortical bone loss only in the presence of
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T Cells and PTH-Induced Bone LossFigure 1. Analysis of the Effects of cPTH in WT Mice, Nude Mice, and Nude Mice Previously Subjected to Adoptive Transfer of WT T Cells
(A) Ex vivo mCT analysis of femur cortical and trabecular bone (n = 12 mice per group).
(B) Serum CTX and osteocalcin levels (n = 12 mice per group).
(C) H&E staining of representative longitudinal sections of distal femurs.
(D) Histomorphometric analysis of femoral trabecular bone volume, formation, and resorption. N. Ob/BS (the number of osteoblasts per mm bone surface) and
ObS/BS (the percentage of bone surface covered by osteoblasts) are indices of bone formation. N. Oc/BS (the number of osteoclasts per mm bone surface), and
OCs/BS (the percentageof bone surface covered byOCs) are indices of bone resorption. BV/TV (the percentage of trabecular volumeoccupied by bone volume) is
an index of bone structure. n = 8–10mice per group. All data are expressed asmean ± SEM. * = p < 0.05 as compared to the corresponding vehicle treated group.T cells. We also show that T cells represent a permissive lineage
that regulates the production of RANKL and OPG by SCs, and
thus their capacity to support PTH induced osteoclastogenesis,
through the CD40L/CD40 signaling system.
RESULTS
cPTH Treatment Fails to Cause Cortical Bone Loss
in T Cell-Deficient Mice
To model the steady-state elevation of PTH levels characteristic
of PHP, hPTH 1-34 was infused intoWT and nude female mice of
10 weeks of age at the rate of 80 mg/kg/day for 2 weeks, a treat-
ment modality referred to hereafter as cPTH. Compared to WT
controls, C57BL/6 nude mice have an increased rate of bone re-
sorption and a lower bone density (Gao et al., 2004; Lee et al.,
2006; Li et al., 2007; Toraldo et al., 2003). To control for these
strain-dependent confounders, the study included nude miceCsubjected to adoptive transfer of WT T cells 2 weeks before ini-
tiation of the PTH treatment. Two weeks after the T cell transfer,
reconstituted nude mice had 60% of the T cells of WT mice
(Figure S1), thus demonstrating that this design allows the
homeostatic expansion of donor T cells to occur prior to treat-
ment with cPTH. cPTH increased serum hPTH 1-34 to 590 ±
14 ng/L, values which are typical of PHP (Potts, 1998).
To assess the differential effects of cPTH on cortical and tra-
becular bone, microcomputed tomography (mCT) was utilized to
analyze femurs harvested at sacrifice. mCT analysis of cortical
bone showed that cPTH induced significant cortical thinning
and loss of cortical volume in WT mice and T cell-reconstituted
nude mice. In contrast, cPTH did not cause significant cortical
bone loss in T cell-deficient nude mice (Figure 1A). mCT analysis
of femoral trabecular bone revealed that cPTH increased trabec-
ular bone volume (BV/TV) in all groups of mice; although, such in-
creasewas lower in nudemice than inWTandTcell-reconstitutedell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc. 133
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T Cells and PTH-Induced Bone Lossmice. Thus, T cells are required for PTH to induce cortical bone
loss but are not essential for the anabolic effect of PTHon trabec-
ular bone.
Additional measurements of vertebral trabecular bone by mCT
confirmed that cPTH increased BV/TV in all groups and revealed
that cPTH induced similar increases in BV/TV in the femur and in
the spine (data not shown). Measurements of serum C-terminal
telopeptide of collagen (CTX), a biochemical marker of resorp-
tion, confirmed (Figure 1B) that nude mice have a higher rate
of resorption than WT mice and showed that adoptive transfer
of T cells into nude hosts leads to a decrease in serum CTX
levels. These phenomena are due, in part, to the capacity of
T cells to induce B cell production of OPG (Li et al., 2007). The
data also revealed that PTH increased resorption in WT mice
and T cell-reconstituted nude mice, but not in T cell-deficient
mice. Serum osteocalcin, a marker of bone formation, was in-
crease by PTH in all groups. The calcemic response of WT and
nude mice to cPTH is shown in Figure S2.
Histomorphometric analysis of femoral trabecular bone re-
vealed (Figures 1C and 1D) that the number of OB per bone
surface (NOb/BS), and the percent of bone surface covered by
OBs (ObS/BS), two indices of bone formation, were significantly
augmented by PTH in all groups. In contrast, cPTH increased
trabecular bone resorption, as assessed by measurements of
the number of OCs per bone surface (NOc/BS) and the OC
surface per bone surface (OcS/BS), in T cell replete, but not in
T cell-deficient mice. Moreover, cPTH increased BV/TV by
30% in WT mice, 33% in nude mice, and 39% in reconsti-
tuted nude mice. These changes approached, but did not reach,
statistical significance. Thus, while T cells are required for cPTH
at 80 mg/kg/day to induce bone resorption and cortical bone
loss, they are not required for cPTH to stimulate bone formation.
Moreover, the capacity of reconstituted nude mice to exhibit a
resorptive response to cPTH demonstrates that nude mice are
protected against the catabolic activity of cPTH at 80 mg/kg/
day because of their T cell paucity, rather than as a result of
a strain-dependent maximal elevation of bone resorption at
baseline. This hypothesis was further confirmed by the finding
that a lethal dose of cPTH (240 mg/kg/day) stimulates bone
resorption in both WT and nude mice (Figure S3).
To confirm that T cells are required for PTH to induce bone
loss, cPTH was infused in class I and class II double MHC/
(Abb/b2 m) mice, a strain characterized by a completed lack of
T cells. While cPTH increased osteocalcin levels in all groups,
cPTH induced cortical bone loss and increased CTX levels in
WT controls, but not in mice lacking T cells (Figure 2A).
The T cells mediating the catabolic effect of cPTH were found
to be ab T cells, because cPTH induced cortical bone loss and
increased serum CTX in WT mice but not in TCRb/ mice,
a strain completely devoiced of ab T cells (Figure 2B). Confirming
that cPTH induced anabolism is independent of T cells, PTH
increased osteocalcin levels in all groups.
To further characterize the subset of T cells required for cPTH
to induce bone loss, nude mice were subjected to adoptive
transfer of either CD4+ or CD8+ T cells and treated with cPTH,
starting 2 weeks after the T cell transfer. While cPTH increased
osteocalcin levels in all groups, cPTH induced cortical bone
loss and increased CTX levels in WT controls, but not in mice
reconstituted with either CD4+ or CD8+ T cells (Figure 2C).134 Cell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier IncFACS analysis of splenocytes harvested prior to initiation of
cPTH treatment revealed that nudemice reconstitutedwith a sin-
gle T cell lineage had a number of either CD4+ T cells or CD8+
T cells, which was similar (86%–100%) to that of nude mice re-
constituted with all T cells (CD90+ cells). However, nude mice
reconstituted with a single lineage had a severe deficit in the
number of T cells of the other lineage. As a result, nude mice re-
constituted with a single T cell lineage had a number of total
T cells, which was only 61%–66% that of nude mice reconsti-
tuted with all T cells. These findings, along with additional
in vitro data shown in Figure 3D (see below), suggest that in
the single T cell lineage reconstitution experiment the catabolic
activity of PTH was silenced by a decrease in the total number
of T cells, rather than by the lack of one T cell population.
In Vivo T Cell Immunodepletion Prevents the Bone Loss
Induced by cPTH in WT Mice
To demonstrate a role for T cells in PTH induced bone loss in
nongenetically manipulated animals, WT female mice were first
depleted of T cells by injection of anti-CD4/CD8 antibodies using
established methods (Chen et al., 2000; Kitaura et al., 2004), and
then treatedwith cPTH for 2weeks, starting 10 days after the first
mAb injection. FACS analysis showed that anti-CD4/CD8 mAbs
had effectively depleted the BM and the spleen of T cells prior to
initiation of cPTH treatment (Figure S4). Analysis of femoral
cortical bone by mCT revealed that in vivo T cell depletion
afforded a significant protection against cPTH-induced cortical
bone loss (Figure 2D). T cell depletion also prevented the in-
crease in the serum level of CTX induced by cPTH. In contrast,
cPTH increased serum osteocalcin in all groups.
Histomorphometric analysis of femoral cortical bone revealed
(Figure 2E) that cPTH increases cortical bone resorption and OC
number in control but not in T cell depleted WT mice. This was
established by measuring the number of OCs per bone surface
(NOc/BS), and the OC surface per bone surface (OcS/BS). Anal-
ysis of trabecular bone showed that BV/TV increased by 23%
and 32% in T cell-depleted and -replete mice, respectively.
However, the changes in BV/TV were not statistically significant.
Thus, studies in nongenetically manipulated mice confirmed
T cells are required for cPTH to induce cortical bone loss and
stimulate bone resorption, while they are not required for cPTH
to stimulate osteocalcin levels, a marker of bone formation.
PTH Fails to Stimulate OC Formation in Cultures
of BM Lacking T Cells
To establish whether T cells are required for PTH to induce OC
formation in vitro, we counted the number of OCs produced by
osteoclastogenic cultures of whole BM. In vitro PTH treatment
(1–10 nm) failed to significantly increase OC formation in BM de-
rived from nude mice, while it did so in BM from both nude mice
previously subjected to adoptive transfer of T cells, andWT con-
trols (Figure 3A). In vitro PTH treatment also failed to stimulate
OC formation in cultures of BM from TCRb/mice (Figure 3B).
To confirm these findings in nongenetically manipulated mice,
BMwas harvested fromWTmice injected with anti-CD4/8 mAbs
or isotype matched irrelevant mAbs for 24 days. BM was then
cultured with vehicle or PTH for 7 days. Although PTH stimulated
osteoclastogenesis in both groups, the number of OCswasmore.
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T Cells and PTH-Induced Bone LossFigure 2. Analysis of the Effects of cPTH in MHC Double KO Mice, TCRb/ Mice, Nude Mice Adoptively Transferred with Either CD4+ or
CD8+ Cells, and WT Mice Treated with anti-CD4/8 or Irrelevant Antibodies
(A) Ex vivo mCT analysis of femur cortical bone, serum CTX, and osteocalcin levels in class I and class II MHC double KO mice (n = 8 mice per group).
(B) Ex vivo mCT analysis of femur cortical bone, serum CTX and osteocalcin levels in TCRb/ mice that lack ab T cells (n = 8 mice per group).
(C) Ex vivo mCT analysis of femur cortical bone, serumCTX and osteocalcin levels in nudemice adoptively transferred with either CD4+ or CD8+ cells (n = 10mice
per group).
(D) Analysis of femur cortical bone by mCT, and serum CTX and osteocalcin levels in WTmice depleted of T cells in vivo by injection of anti CD4/8 mAbs. Controls
were treated with irrelevant (Irr) mAbs (n = 9 mice per group).
(E) Analysis of femur cortical and trabecular bone by histomorphometry in WT mice treated in vivo with anti CD4/8 or irrelevant antibodies (n = 9 mice per group).
All data are expressed as mean ± SEM. * = p < 0.05 as compared to the corresponding vehicle treated group.than 5-fold lower in BM from T cell-depleted mice than in BM
from T cell-replete controls (Figure 3C).
Finally, BMwas harvested fromWTmice, depleted in vitro of all
T cells (CD90+ cells), CD4+, or CD8+ T cells by negative immuno-
magnetic selection, and cultured with PTH for 7 days (Figure 3D).
Controls included T cell-depleted BM immediately reconstituted
with 10% or 20% T cells, a 2- to 4-fold superphysiologic propor-
tion selected to account for the diminished survival in vitro of pu-
rified T cells. PTH failed to stimulateOC formation in BMdepleted
of either CD4+ or CD8+ T cells, while the addition of CD4+ or
CD8+ cells to T cell-depleted BM dose dependently increasedCethe osteoclastogenic activity of PTH. These findings confirm
that CD4+ or CD8+ cells are both capable of promoting PTH-in-
duced OC formation, and that such response is a function of the
number of T cells rather than their phenotype. Representative im-
ages of T cell-depleted BM cultures stained for tartrate-resistant
acidphosphatase (TRAP) to visualizeOCsare shown in Figure 3E.
T Cells Regulate the Number and the Osteoclastogenic
Activity of SCs
To investigate whether T cells regulate the number of BM SCs,
BM was harvested from nude mice and WT mice depleted ofll Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc. 135
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T Cells and PTH-Induced Bone LossFigure 3. PTH Has a Reduced Capacity to Stimulate In Vitro OC Formation in the Absence of T Cells
(A and B) BM from nude and TCRb/ mice and from the respective controls were stimulated with PTH for 7 days, stained for TRAP, and OCs counted.
* = p < 0.05 and ** p < 0.01 as compared to vehicle.
(C) BM from WT mice treated in vivo with anti CD4/8 mAbs for 24 days was cultured with PTH for 7 days. * = p < 0.05 as compared to vehicle treated BM,
** = p < 0.05 as compared to PTH treated BM from T cell-depleted mice.
(D)WTBMwas depleted of T cells (CD90+ cells) or CD4+ or CD8+ cells in vitro. Controls included BMdepleted of T cells and immediately reconstitutedwith 10%–
20% BM T cells, CD4+ or CD8+ T cells. All samples were stimulated with PTH for 7 days, stained for TRAP, and OCs counted. * = p < 0.05 and ** = p < 0.01
compared to the other groups.
(E) Images of PTH treated BM stained for TRAP to visualize OCs. Samples stimulated with RANKL andM-CSF were used as a positive control. OCs were defined
as multinucleated (R3 nuclei) TRAP+ cells. All data are expressed as mean ± SEM.T cells for 24 days in vivo by injection of anti-CD4/8 mAbs. Fur-
thermore, WT BMwas depleted of T cells in vitro by negative im-
munomagnetic selection using beads coupledwith anti-CD4 and
anti-CD8 mAbs. Controls included nude mice reconstituted with
T cells 2weeks earlier,WTmice treatedwith irrelevantmAbs, and
BM depleted of T cells in vitro immediately reconstituted with
a physiologic number of BM T cells. Since SCs proliferate rapidly
for 1 week after adhering to plastic (Quarles et al., 1992), all BM
samples were cultured for 7 days to allow SCs to increase in
number. SCs were then purified and counted. This analysis re-
vealed that BM lacking or depleted of T cells had%50% fewer
SCs as compared to T cell-replete cultures (Figures 4A–4C).
To investigate the mechanism involved, SCs were purified as
described above, seeded in equal number, cultured for 3 days,136 Cell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Incand used to determine their rate of proliferation and apoptosis
by thymidine incorporation and TUNEL staining. SCs from BM
lacking or depleted of T cells exhibited an 2- to 3-fold lower
proliferation (Figures 4D–4F), and an 2- to 3-fold higher rate
of apoptosis (Figures 4G–4I), as compared to SCs from T cell-re-
plete BM, demonstrating that T cells provide survival and prolif-
eration signals to SCs. Thus, one mechanism by which T cells
affect the osteoclastogenic response to PTH is by regulating
the size of the SC pool in the BM.
To determine whether T cells regulate SC function, WT mice,
nude mice, and nude mice previously reconstituted with WT
T cells were infused with cPTH for 2 weeks. BM was harvested
and cultured for 1 week. SCs were then purified, seeded in equal
number, and cultured for 3 days with and without PTH, and their.
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T Cells and PTH-Induced Bone LossFigure 4. Effects of T cells on SC Number, Proliferation, and Apoptosis
(A–C) SCs were purified from BM harvested from T cell deficient nude mice, WT mice depleted of T cells in vivo via injection of anti CD4/8 mAbs, and WT mice
depleted of T cells in vitro by immunomagnetic selection. Control groups included nude mice subjected to adoptive transfer of spleen WT T cells 2 weeks earlier,
BM from WT mice treated with irrelevant mAbs, and WT mice first depleted of T cells in vitro and immediately reconstituted with WT BM T cells. n = 3 wells per
group. (A)–(C) show number of SCs/mouse yielded by the purification procedure. * = p < 0.05 as compared to the other groups.
(D–F) SC proliferation assay. SCs were purified as described in the methods, seeded in equal number, cultured for 3 days, and pulsed with thymidine for the last
18 hr of culture. Data are expressed in CPM. * = p < 0.05 as compared to the other groups.
(G–I) Percent analysis of the rate of SC apoptosis. SCs were cultured for 3 days and their rate of apoptosis determined by TUNEL staining at the end of the culture
period. * = p < 0.05 as compared to the other groups. All data are expressed as mean ± SEM.production of RANKL and the soluble RANKL decoy receptor
OPG mRNA was assessed by real-time RT-PCR. As compared
to SCs from T cell-replete controls, SCs from nude mice treated
with vehicle expressed lower mRNA levels of both RANKL and
OPG (Figure 5A). However, the RANKL/OPG mRNA ratio
was similar in all vehicle-treated groups. cPTH increased the
expression of RANKL mRNA and lowered that of OPG mRNA
in SCs from T cell-replete mice but not in those from nude
mice. As a result, SCs from cPTH-treated T cell-deficient nude
mice demonstrated a lower RANKL/OPG mRNA ratio asCcompared to SCs from cPTH-treated WT and reconstituted
nude mice.
To confirm these findings in an in vitro model, WT BM was
depleted of T cells in vitro by negative immunomagnetic selec-
tion and cultured for 1 week. Controls included whole BM and
BM, which was first depleted of T cells, and immediately recon-
stituted with BM T cells. SCs were then purified and cultured
for 3 days with or without PTH. Unstimulated SCs from
T cell-depleted BM expressed lower mRNA levels of RANKL
and OPG than those from T cell replete BM (Figure 5B).ell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc. 137
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T Cells and PTH-Induced Bone LossFigure 5. Effect of T Cells on RANKL/OPG mRNA Expression by BM SCs and SC Osteoclastogenic Activity
(A) mRNA levels of RANKL and OPG and RANKL/OPG mRNA ratio in SCs from nude mice. * = p < 0.05 as compared to the corresponding vehicle group.
** = p < 0.05 as compared to the corresponding WT and T cell reconstituted groups.
(B) mRNA levels of RANKL andOPG and RANKL/OPGmRNA ratio in SCs fromWTmice depleted of T cells in vitro. * = p < 0.05 as compared to the corresponding
vehicle group. ** = p < 0.05 as compared to the corresponding WT and T cell reconstituted groups.
(C)BMMsandTcells fromWTmicewerecoculturedwithSCsfromnudeandcontrolmicefor1weekinthepresenceofPTH.CocultureswerestainedforTRAPandOCscounted.
* = p < 0.05 compared to vehicle. ** = p < 0.05 compared to vehicle and to the corresponding PTH treated groups with SCs fromWT and T cell-reconstituted nudemice.138 Cell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc.
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lated SCs from all groups. In this model, stimulation with PTH
increased the expression of RANKL in all groups, and de-
creased the levels of OPG mRNA in SCs from T cell replete
BM, but not in those from T cell-depleted BM. Therefore, the
RANKL/OPG mRNA ratio was lower in PTH-stimulated SCs
from T cell-depleted BM than in control SCs. These findings
demonstrate that SCs, which have matured both in vitro and
in vivo in a microenvironment lacking BM T cells exhibit an
altered RANKL/OPG ratio.
To assess the capacity of SCs to support PTH-induced osteo-
clastogenesis, T cells and BM macrophages (BMMs) harvested
from untreated WT mice were cocultured for 7 days with equal
numbers of SCs from either nude mice or T cell-replete controls
in the presence of PTH, a hormone that promotes OC formation
by targeting SCs. Under these conditions PTH-induced OC
formation is a function of SC osteoclastogenic activity. Since
the physiologic SC/BMM ratio in the BM is1/1000, initial exper-
iments were conducted using this ratio of SCs and BMMs, but
PTH failed to induce OC formation in all groups (data not shown).
Therefore, in subsequent experiments the SC/BMM ratio was set
at 200/1 to favor OC formation. SCs from T cell-deficient nude
mice exhibited a lower osteoclastogenic response to PTH (Fig-
ure 5C), as compared to SCs from WT and reconstituted nude
mice, suggesting that the lack of T cells in the BMmicroenviron-
ment leads to the emergence of SCs characterized by blunted
osteoclastogenic activity. This phenomenon was evident in spite
of the presence of T cells in the osteoclastogenic cultures,
suggesting that the 7-day-long culture period was not sufficient
for T cells to modify the osteoclastogenic phenotype of SCs
harvested from T cell-deficient mice.
To confirm these findings, WT BM was depleted of T cells
in vitro. T cell-reconstituted BM was prepared by first depleting
the BM of T cells, followed by the immediate addition of a phys-
iologic number of CD4+ and CD8+ BM T cells. BM was then
cultured for 1 week to expand the SC pool. SCs were then puri-
fied and cocultured for 7 days with T cells and BMMs from
untreated WT mice in the presence of PTH. The number of
OCs produced by these cocultures was counted at the end of
this 1 week culture period.
This experiment revealed that in spite of the presence of T cells
in the osteoclastogenic culture, SCs from T cell- depleted BM
exhibited a lower osteoclastogenic activity (Figure 5D) than
those from T cell-replete BM. Together, these findings indicate
that the lack of T cells in the BM microenvironment leads to
the emergence of SCs characterized by a blunted capacity to
support PTH induced OC formation. This phenomenon is likely
to result from impaired production of RANKL not sufficiently off-
set by a decrease in OPG.
To determine whether T cells regulate the capacity of BMMs to
differentiate into OCs, SCs and T cells fromWTmice were cocul-
tured with BMMs from either nude or WTmice in the presence of
PTH for 1 week. All cultures, regardless of the BMM source, pro-
duced the same number of OCs (Figure S5A). Furthermore,
purified BMMs fromWT and nudemice formed the same numberCeof OCs in response to stimulation with M-CSF and a suboptimal
concentration of RANKL (Figure S5B). Thus nude mice do not
have defective OC precursors.
T Cells Stimulate SC Osteoclastogenic Activity
through CD40L
One feature of activated T cells is that of expressing CD40L, a re-
ceptor for the costimulatory molecule CD40, which is expressed
on cells of the osteoblastic lineage (Ahuja et al., 2003). Accord-
ingly, we found that 22% of stimulated CD4+ and CD8+ BM
T cells were CD40L+ (Figure S6A). However, cPTH treatment
did not further increase T cell activation and T cell CD40L expres-
sion (data not shown). In contrast, RT-PCR and western blot
analysis revealed that cPTH upregulates CD40 mRNA and
CD40 protein expression in SCs from WT mice but not from
nude mice (Figures S6B and S6C), suggesting that PTH upregu-
lates the expression of CD40 only in SCs that havematured in the
presence of T cells.
To determine whether BM T cells regulate the osteoclasto-
genic activity of SCs through CD40L/CD40 signaling, WT and
CD40/ SCs were cocultured with BMMs and PTH to induce
OC formation. The formation of OCs induced by PTH was re-
duced in cultures containing CD40/ SCs (Figure 6A). More-
over, while T cells increased OC formation in cultures with WT
SCs, T cells failed to increase OC formation in those with
CD40/ SCs. Neutralization of CD40L by the anti-CD40L
mAb MR-1 also blocked the capacity of T cells to increase
PTH-induced OC formation, while the addition of soluble
CD40L to cocultures of SCs and BMMs increased SC osteoclas-
togenic activity in a manner identical to the addition of T cells. In
contrast, soluble CD40L did not increase OC formation in cul-
tures of BMMs alone stimulated with M-CSF and RANKL (not
shown), suggesting that CD40 signaling in BMMs does not
regulate the capacity of BMMs to differentiate into OCs.
Further confirming the relevance of CD40L/CD40 signaling,
the osteoclastogenic activity of PTH was markedly blunted in
CD40/ and CD40L/ BM (Figure 6B). Moreover, experi-
ments in which BM from WT mice was depleted of T cells
in vitro and reconstituted with BM T cells from either WT mice
or CD40L/ mice revealed that the addition of WT T cells
rescues PTH induced osteoclastogenesis, while reconstitution
with CD40L/ T cells is only 20% effective.
SCs purified from CD40L/ BM after 1 week of culture
in vitro also exhibited a reduced rate of proliferation and in-
creased apoptosis (Figure 6C). To provide an additional confir-
mation of the capacity of CD40L to regulate SC function, WT
BM was cultured for 1 week. SCs were then purified and incu-
bated with soluble CD40L for 7 days. These studies revealed
that CD40L increases SC thymidine incorporation by 50%,
decreases SC apoptosis by 2-fold (Figure 6D), and increases
the RANKL/OPGmRNA ratio (Figure 6E). Thus, CD40L increases
SC proliferation and life span, and causes the formation of SCs
with increased osteoclastogenic potentials.
To demonstrate the relevance of CD40L in vivo, CD40L/
mice and congenic WT controls were infused with cPTH for 2(D) BMMs and T cells from WT mice were cocultured for 1 week in the presence of PTH with SCs from either WT BM depleted of T cells in vitro or control BM.
* = p < 0.05 compared to vehicle. ** = p < 0.05 compared to vehicle and to PTH treated groups with SCs fromwhole and reconstituted BM. All data are expressed
as mean ± SEM.ll Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc. 139
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T Cells and PTH-Induced Bone LossFigure 6. T Cells Regulate SC Activity and Mediate PTH-Induced Bone Loss through CD40L
(A) SCs fromWT or CD40/mice were cocultured with BMMs and T cells fromWTmice in the presence of PTH for 7 days. Anti-CD40LmAb and soluble CD40L
were added to same samples. The cocultured were then stained for TRAP and the OCs counted. * = p < 0.05 compared to vehicle. ** = p < 0.05 compared to all
other groups. *** = p < 0.05 compared to corresponding groups with WT SCs.
(B) Whole BM fromWT, CD40/, and CD40L/mice was cultured with PTH for 7 days and stained for TRAP andOCs counted. In some samples, WT BMwas
depleted of T cells in vitro and reconstituted with either WT or CD40L/ T cells. * = p < 0.05 compared to vehicle. ** = p < 0.05 as compared to all other groups.140 Cell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc.
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T Cells and PTH-Induced Bone Lossweeks. mCT analysis revealed that cPTH decreases femoral corti-
cal thicknessandvolumeand increasesserumCTX inWTmicebut
not in CD40L/mice (Figure 6F). Finally, T cells harvested from
CD40L/ mice were adoptively transferred into TCRb/
mice. After 10weeks, the shortest time that preliminary studies re-
vealed to be required for T cells to rescueSC function in this strain,
reconstitutedmicewere infusedwith cPTH for 2weeks. Again, we
found that cPTH induces cortical bone loss and increases serum
CTX levels in TCRb/ mice reconstituted with WT T cells, but
not in mice injected with CD40L/ T cells (Figure 6G). Together,
these findings demonstrate that cPTH stimulate bone resorption
and cause bone loss through T cell expressed CD40L.
DISCUSSION
We report that mice lacking T cells are protected against the loss
of cortical bone and the stimulation of bone resorption induced
by cPTH, thus indicating that T cells represent a regulatory
component of the BM microenvironment involved in the osteo-
clastogenic response to PTH. This response is induced by
PPR signaling in SCs and their osteoblastic progeny, but
T cells play a permissive role by promoting the osteoclastogenic
activity of SCs through membrane-bound CD40L (Figure 7). We
also show that the PTH permissive activity of T cells is not a fea-
ture of a specific lineage, but rather depends on the presence of
a sufficient number of either CD4+ or CD8+ T cells.
Transplantationof tumorsproducingPTHand/orPTHrP innude
mice stimulates bone resorption in spite of the absence of T cells
Figure 7. Schematic Representation of the
Role of T Cells in the Mechanism by which
PTH Stimulates OC Formation
In the absence of T cells (left panel), BM SCs are fewer
in number (not shown) and exhibit a blunted capacity
to support PTH-induced OC formation due to dimin-
ished production of RANKL and continuous produc-
tion of the RANKL decoy receptor OPG. In the pres-
ence of T cell-expressed CD40L (right panel), the
pool of SCs in the BM is 2-fold larger (not shown).
Furthermore, CD40L/CD40 signaling increases the
osteoclastogenic activity of SCs by augmenting the
SC production of RANKL and blunting their secretion
of OPG. The result is a potentiation of the capacity of
PTH to stimulate the formation of OCs.
in the host (Guise et al., 1992; Mehdizadeh
et al., 1989; Uy et al., 1995). The apparent dis-
crepancy between these reports and ours is
explained by the higher levels of circulating
PTH/PTHrP attained by transplanting PTH/
PTHrP-producing tumors, as compared to
those obtained by infusing PTH at 80 mg/kg/day. In support of
this hypothesis are our findings demonstrating that cPTH at 240
mg/kg/day,adose that elevatescirculatingPTHto levelsobserved
in mice bearing PTH/PTHrP-producing tumors (R1000 ng/L),
stimulates bone resorption and induces hypercalcemia in T cell-
deficient nude mice, although less potently than in WT mice. In
contrast, cPTH at 80 mg/kg/day, a dose that raises serum PTH
to a level typical of PHP, stimulates bone resorption only in
T cell-replete mice. Adding further support to our hypothesis,
are reports from others demonstrating that transplantation of
adenomatous and hyperplastic parathyroid tissues in nude mice
in a fashion that elevatesserumPTH to80–240ng/L fails to induce
hypercalcemia (Hory et al., 2000; Strieth et al., 2005), while para-
thyroid transplants that elevate serumPTH toR1000 ng/L induce
hypercalcemia in nude hosts (Schachter et al., 1990). A likely
hypothesis is that extreme levels of PTH/PTHrP induce SC/OBs
expression of osteoclastogenic factors in an amount sufficient
to maximally stimulate OC formation and activity even in the
absence of T cells. Alternatively, extreme levels of PTH/PTHrP
could alter theproduction of RANKL and OPG by other BM cells
that are not key targets of physiologic levels of PTH. For exam-
ple, the B cell production of OPG, which represents 65% of
the total BMOPG (Li et al., 2007), might be blunted by high levels
of PTH, as the functional activity of B cells is repressed by PTH
(Alexiewicz et al., 1990; Shurtz-Swirski et al., 1995).
cPTH is known to stimulate both the resorption and the forma-
tion of trabecular bone (Dempster et al., 1999; Iida-Klein et al.,
2005; Qin et al., 2004; Zhou et al., 2001). Since we found that(C and D) SCswere purified as described in the methods, cultured for 7 days with vehicle or soluble CD40L (1 mg/ml) and pulsed with thymidine for the last 18 hr to
measure SC proliferation. SC apoptosis was determined by TUNEL staining at the end of the 7 day culture period. * = p < 0.05 compared to WT SCs or vehicle.
(E) mRNA levels of RANKL and OPG and RANKL/OPG mRNA ratio in SCs stimulated by soluble CD40L (1 mg/ml). * = p < 0.05 compared to vehicle.
(F) Ex vivo mCT analysis of femur cortical bone and serum CTX levels in WT and CD40L/mice treated with cPTH (80 mg/kg/day) for 2 weeks. n = 10 mice per
group. * = p < 0.05 compared to the corresponding vehicle treated group.
(G) Ex vivo mCT analysis of femur cortical bone and serum CTX levels in TCRb/ reconstituted with CD40L/ T cells. Reconstituted mice were treated with
cPTH (80 mg/kg/day) for 2 weeks. n = 12mice per group. * = p < 0.05 compared to the corresponding vehicle treated group. The numbers next to the bars indicate
the percent difference between the corresponding vehicle and the PTH treated group. All data are expressed as mean ± SEM.Cell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier Inc. 141
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T Cells and PTH-Induced Bone Lossthe lack of T cells abrogates the capacity of cPTH to stimulate
bone resorption but not bone formation, it would be predicted
that cPTH would cause a greater increase in BV/TV in T cell-
deficient animals than in T cell-replete mice. By contrast, cPTH
increased BV/TV in all groups. A likely explanation for this finding
is that the diminuished osteoclastogenic response to cPTH
obseved in T cell-deficient mice blunts a permissive osteoclastic
signal required for PTH to stimulate trabecular bone growth
(Koh et al., 2005).
In spite of a smaller SC pool and a blunted SC osteoclasto-
genic activity, T cell-deficient mice possess a normal anabolic
response to cPTH. This may suggest that the SCs that produce
osteoclastogenic factors and support OC formation are not the
same cells that differentiate into OBs, the cells that form osteoid
and mineralize it, a hypothesis recently proposed by others
(O’Brien et al., 2006). Indeed osteoclastogenic SCs express
intercellular adhesion molecule-1 (ICAM-1), which is necessary
for binding to OC precursors (Tanaka et al., 2000), while matrix
producing osteoblastic cells are ICAM-1 negative (Everts et al.,
2002). However, it is also possible that a defective stimulation
of bone formation might emerge in T cell-deficient mice in
response to long-term cPTH treatment.
The BM contains activated memory T cells that express li-
gands for surfacemolecules expressed by cells of the osteoblas-
tic lineage (Ahuja et al., 2003). Among them is CD40L, which is
known to promote OB survival through binding to OB expressed
CD40 (Ahuja et al., 2003). Our findings demonstrate that CD40L
signaling provides survival and proliferation cues to SCs and reg-
ulates their function by increasing the RANKL/OPG ratio. These
quantitative and qualitative changes provide a molecular expla-
nation for the reduced capacity of SCs from T cell-deficient BMs
to support OC formation in vitro. The relevance of T cell
expressed CD40L in vivo was confirmed by the failure of PTH
to induce cortical bone loss and stimulate bone resorption in
both CD40L/ mice and T cell-deficient mice reconstituted
with CD40L/ T cells. Together these data demonstrate that
T cells increase PTH induced osteoclastogenesis through
a CD40L/CD40-mediated crosstalk between T cells and SCs.
Since CD40 is expressed not only in SCs but also in OC pre-
cursors of the monocytic lineage (O’Sullivan and Thomas,
2003), it could be argued that T cell-expressed CD40Lmay stim-
ulate OC formation through direct signaling in maturing OCs.
This is unlikely because neither anti-CD40L mAb nor soluble
CD40L alters OC formation in cultures of BMMs and T cells stim-
ulated with RANKL and M-CSF (data not shown).
Antigen-activated Th2 cells have been shown to produce PTH,
which contributes to maintain the anabolic activity of OBs under
inflammatory conditions (Young et al., 2005). It is unlikely that
mice lacking T cells are protected against the catabolic activity
of cPTH because of the absence of Th2 cell produced PTH. In
fact, activated Th2 cells mitigate bone resorption by lowering
the RANKL/OPG ratio largely through PTH-independent mecha-
nisms (Young et al., 2005).
Previous studies have shown that T cells play a pivotal role in
stimulating OC formation and inducing bone loss in inflammatory
diseases (Kong et al., 1999), periodontal bone disease (Taubman
and Kawai, 2001), and estrogen deficiency (Weitzmann and
Pacifici, 2005) through upregulated production of RANKL and
TNF by activated T cells (Kong et al., 1999; Weitzmann and142 Cell Metabolism 8, 132–145, August 6, 2008 ª2008 Elsevier IncPacifici, 2005). The current investigation demonstrates the key
role of CD4+ and CD8+ T cells in a model of hyperparathyroid-
ism, another common condition characterized by stimulated os-
teoclastogenesis, increased bone turnover and bone loss (Potts,
1998; Riggs and Melton, 1986). Together, these data suggest
that T cells may be central for stimulating OC formation above
baseline both in inflammatory and hormone-mediated bone
loss. However, T cells mediate PTH-induced bone loss by regu-
lating SC function through a membrane-bound signaling mole-
cule, while they cause other forms of bone loss by secreting os-
teoclastogenic cytokines.
Cortical bone represents about 80% of the entire skeletal
mass (Riggs et al., 2002), and cortical volume and thickness
are major predictors of bone strength and fracture risk (Cheng
et al., 2006). Thus, the T cell-dependent bone effects of PTH
are relevant for the risk of long bone fractures associated with
primary and secondary hyperparathyroidism (Grey et al., 1996;
Parisien et al., 2001; Potts, 1998; Riggs and Melton, 1986). Un-
derstanding the crosstalk between T cells and SCs may thus
yield novel therapeutic strategies for PTH induced bone disease.
EXPERIMENTAL PROCEDURES
Animals
All animal procedures were approved by the Institutional Animal Care and
Use Committee of Emory University. All experiments were conducted in
female mice of 10 weeks of age. C57BL/6 WT mice, homozygous nude mice
(nu/nu), Abb/b2 m mice, TCRb/, CD40/, and CD40L/ mice were
purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were
maintained pathogen-free conditions. Animals were fed sterilized food and
water.
T Cell Transfer
Nude and TCRb/ mice were subjected to adoptive transfer of WT spleen
T cells via tail-vein injection of 23 106 T cells purified by positive immunomag-
netic selection usingMACSMicrobeads (Miltenyi Biotec, Auburn, CA) coupled
to anti-CD90 (Thy1.2), anti-CD4, or anti-CD8 antibodies. T cells were trans-
ferred into nude mice 2–10 weeks before treatment to allow the engraftment
and the peripheral expansion of the transferred T cells, as well as the recovery
of SC function.
In Vivo PTH Infusion
Eighty micrograms per kilograms per day of hPTH1-34 (Bachem California,
Inc., Torrance, CA) or vehicle were delivered for 2 weeks by implanting ALZET
osmotic pump model-1002 (DURECT corporation, Cupertino, CA) with a
delivery rate of 0.25 ml/hr.
In Vivo T Cell Depletion
WT mice were depleted of T cell subsets by IP injections of bioreactor-gener-
ated mAbs GK1.5 (ATCC, Manassas VA) and 2.43 (ATCC), which are directed
against CD4+ and CD8+ cells, respectively (Chen et al., 2000), or irrelevant
isotype matched control mAbs at the dose of 500 mg each twice a week for
24 days (Grcevic et al., 2000; Kitaura et al., 2004), starting 10 days before
the PTH or vehicle infusion. Depletion efficiencies were confirmed by flow
cytometry, and depleted subsets of lymphocytes were routinely obtained
(Figure S4).
In Vitro T Cell Depletion
Whole BM was harvested from WT mice and depleted of T cells by negative
immunomagnetic selection using beads coupled with anti-CD4 and anti-
CD8 mAbs. T cell-reconstituted BM was prepared by first depleting the BM
of T cells, followed by the immediate addition of a physiologic number of
CD4+ and CD8+ BM T cells..
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BM was collected from long bones by centrifugation for 2 min at 13,000 rpm,
and cultured for 7 days in a-MEMmedium containing 10% FBS, 100 mg/ml of
penicillin, and 100 IU/ml of streptomycin. After discarding the nonadherent
cells, adherent BMMs were eliminated by positive immunoselection by
MACS Microbeads (Miltenyi Biotec, Auburn, CA) coupled to anti-CD11c anti-
body. This marker is expressed on nonadherent DCs and adherent BMMs
(Corbi and Lopez-Rodriguez, 1997). The remaining adherent cells were SCs.
Cell purity was verified by histochemical staining for nonspecific esterase,
a marker for cells of the monocytic/macrophage lineage. Purified SCs were
>95% nonspecific esterase negative. When cultured in the presence of 50
mg/ml of ascorbic acid and 5 mM b-glycerophosphate to induce differentiation
toward the osteoblastic lineage SCs were >95% positive for alkaline phospha-
tase (ALP), a marker of differentiated BM SCs.
BMM and T Cell Purification and Culture
BMMs and T cells were purified from the BM and spleen by positive immuno-
selection using MACS Microbeads (Miltenyi Biotech) coupled to anti-CD11b,
anti-CD90, or anti-CD4 and anti-CD8 antibodies, as described (Cenci et al.,
2003). Cell purity was verified to be >90% by FACS. T cell-conditioned media
was prepared by culturing purified T cells with plate bound anti-CD3 and
anti-CD28 mAbs for 3 days.
In Vitro OC Generation
BM or cultures of BMMs, SCs, and T cells were cultured for 7 days in the pres-
ence of human PTH 1-34 (0.1–10 nM) to induce OC formation. The cultures
were then fixed and stained for TRAP. TRAP-positive cells with R3 nuclei
were scored as OCs.
mCT Measurements of Cortical Bone
mCT scanning and analysis was performed as reported previously (Gao et al.,
2007)bya technicianblind togroupingof animals, usingaScancomCT-40scan-
ner (ScancoMedical, Bassersdorf, Switzerland). Bones were scanned at a res-
olution of 12 mm, tomographic imageswere obtained at conditions of 70KV and
114 mA by collecting 500 projections. Cortical bone volume and cortical thick-
ness were determined by analyzing 80 slices at themiddiaphysis of the femurs.
Quantitative Bone Histomorphometry
Bone histomorphometry analysis was performed at the University of Alabama
at Birmingham, Center for Metabolic Bone Disease—Histomorphometry and
Molecular Analysis Core Laboratory by using Bioquant Image Analysis soft-
ware (R&M Biometrics, Nashville, TN). The measurements, terminology, and
units used for histomorphometric analysis were those recommended by the
Nomenclature Committee of the American Society of Bone and Mineral
Research (Parfitt et al., 1987). Femurs were decalcified with 20% EDTA in
PBS, embedded in paraffin, sectioned, and stained with hematoxylin and
eosin (H&E) and TRAP. For analysis of trabecular bone, measurements were
obtained in an area of cancellous bone that measured approximately 2.5
mm2, contained only secondary spongiosa, and was located 0.5–2.5 mm
proximally to the distal epiphyseal growth cartilage of femurs. For analysis of
cortical bone, measurements were obtained in cross-sections of the central
region of the distal femur. N.Ob/BS (the number of OBs per mm bone surface),
ObS/BS (the percentage of bone surface covered byOBs), N.OC/BS (the num-
ber of OCs per mm bone surface), OcS/BS (the percentage of BS occupied by
OCs), ES/BS (the percentage of eroded bone surfaces), and BV/TV (the per-
centage of total volume occupied by trabecular bone volume) were measured.
Measurement of Serum Calcium and PTH
Serum calcium was measured by a colorimetric kit, Calcium LiquiColor (Stan-
bio Laboratory, Boerne, TX). Serum human PTH1-34 levels were measured in
PTH treated mice to verify the successful delivery of human PTH1-34 using
a human 1-34 PTH ELISA kit, which does not crossreact with mouse 1-34
PTH (Immutopics, Inc., San Clemente, CA).
Measurement of Serum Markers of Bone Turnover
Serum C-terminal telopeptide of collagen (CTX), a marker of bone resorption,
was measured by a rodent-specific ELISA assay (Nordic Bioscience Diagnos-
tics A/S, Herlev, Denmark). Serum osteocalcin, a specific marker for boneCformation, was measured using Rat-MID Osteocalcin ELISA kit (Nordic Bio-
science Diagnostics A/S, Herlev, Denmark).
Thymidine Incorporation Assay
SCproliferation was quantitated by thymidine incorporation. SCswere seeded
in equal number, cultured for 3 days, and pulsed with 3H-thymidine (0.5 mCi/
well), added during the last 18 hr of culture. Cells were harvested by using
a Cell Harvester (Skatron, Sterling, VA) and thymidine incorporation deter-
mined on a Packard TRI-CARB 4640 liquid Scintillation Counter.
Apoptotic Cell Assay
SCs were seeded in equal number and cultured for 3 days. Apoptotic SCs
were stained by DeadEnd Colorimetric TUNEL System (Promega, Madison,
WI) according to the manufacturer’s instruction. The number of apoptotic cells
were counted and expressed as a percentage of total cells.
Real-Time RT-PCR
RANKL and OPGmRNA were quantitated by real-time PCR using a GeneAmp
7000 system (PE Biosystems) as previously described (Cenci et al., 2003). All
primers for real-time PCR were designed by using Primer Express Software
v2.0 (PE Biosystems). The primers used were 50-CAC AGC GCT TCT CAG
GAG CT-30 (forward) and 50-CAT CCA ACC ATG AGC CTT CC-30 (reverse)
for RANKL, and 50-CTT GGG TCT GTT GCT TGG TGA-30 (forward) and 50-
GCCGCT TCC TTA CAC ACCAG-30 (reverse) for OPG.mRNAwas normalized
against b-tubulin by using the primers 50-GGA GAG CTG TGA TTG CCT GC
(forward) and 50-CCA CCC AGT GAG TGG GTC AG-30 (reverse). Amplification
reactions were performed in 25 ml containing 0.5 mM of primers, dNTPs
(0.2 mM each) in PCR buffer and 0.03 U Taq polymerase along with SYBR-
green (Molecular Probes, Eugene, OR). Dissociation curves revealed a single
product in all cases. Fold change in cDNA concentration was calculated as
described (Cenci et al., 2003) with normalization of input using b-tubulin.
Statistical Analysis
For each outcome, a two-way analysis of variance was applied that included
the main effects for animal strain and treatment plus the statistical interaction
between animal strain and treatment. When the statistical interaction between
animal strain and treatment group was not statistically significant (p > 0.05) nor
suggestive of an important interaction (p > 0.10), p values for the main effects
tests were reported.When the statistical interactionwas statistically significant
or suggestive of an important interaction, then t tests were used to compare
the differences between the treatment means for each animal strain, applying
the Bonferroni correction for multiple comparisons. Simple comparisons were
made using unpaired Student’s t test to evaluate the effects of sCD40L on SC
proliferation and apoptosis.
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